Bevacizumab-800CW [53, 54], cetuximab-800CW [55, 56] and SGM-101 [57], targeting, respectively, VEGF-A, EGFR, and CEA, are currently being investigated for the detection of resection margins of the primary tumour and (lymph node) metastases. Here, VEGFA is linked to neoplasm.